Prothena (NASDAQ:PRTA) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.

A number of other equities research analysts also recently weighed in on PRTA. Deutsche Bank reaffirmed a “buy” rating on shares of Prothena in a research report on Sunday, October 1st. Royal Bank of Canada reaffirmed a “buy” rating on shares of Prothena in a research report on Friday, September 29th. SunTrust Banks reaffirmed a “buy” rating and set a $75.00 price objective on shares of Prothena in a research report on Monday, October 2nd. Jefferies Group reaffirmed a “buy” rating and set a $100.00 price objective on shares of Prothena in a research report on Monday, October 2nd. Finally, BTIG Research dropped their price objective on Prothena from $80.00 to $77.00 and set a “buy” rating on the stock in a research report on Friday, September 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $76.75.

Prothena (NASDAQ:PRTA) opened at $38.54 on Friday. Prothena has a 12-month low of $35.77 and a 12-month high of $70.00.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.41) by $0.04. Prothena had a negative return on equity of 34.40% and a negative net margin of 562.19%. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the prior year, the company earned ($1.26) EPS. The business’s revenue was down 33.6% compared to the same quarter last year. sell-side analysts predict that Prothena will post -4.27 EPS for the current year.

In other Prothena news, insider Gene G. Kinney sold 2,800 shares of the stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $70.00, for a total value of $196,000.00. Following the completion of the sale, the insider now directly owns 5,593 shares in the company, valued at $391,510. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Tara Nickerson sold 17,500 shares of the stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $63.60, for a total value of $1,113,000.00. Following the completion of the sale, the insider now owns 19,500 shares of the company’s stock, valued at $1,240,200. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,424 shares of company stock valued at $1,922,787. 3.10% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can raised its stake in shares of Prothena by 6.7% in the second quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 117 shares during the last quarter. Quantbot Technologies LP raised its stake in shares of Prothena by 672.7% in the second quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 1,628 shares during the last quarter. Strs Ohio raised its stake in shares of Prothena by 69.2% in the third quarter. Strs Ohio now owns 2,200 shares of the biotechnology company’s stock worth $142,000 after purchasing an additional 900 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Prothena by 187.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 1,549 shares during the last quarter. Finally, Fieldpoint Private Securities LLC purchased a new position in shares of Prothena in the third quarter worth about $162,000.

COPYRIGHT VIOLATION WARNING: “Prothena (PRTA) Rating Lowered to Sell at ValuEngine” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/12/17/prothena-prta-rating-lowered-to-sell-at-valuengine.html.

Prothena Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Stock Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related stocks with our FREE daily email newsletter.